The psoriatic arthritis treatment market is a critical segment of the pharmaceutical industry, providing advanced therapies for patients with psoriatic arthritis, a chronic inflammatory joint disease associated with psoriasis. With rising prevalence of psoriatic arthritis, growing demand for biologic therapies, advancements in treatment options, and increasing awareness of psoriatic arthritis, this market is experiencing robust growth.

The market was valued at USD 5.8 billion in 2024, about USD 6.2 billion in 2025, and is projected to reach roughly USD 12.0 billion by 2035, growing at a CAGR of approximately 6.8%. Growth is driven by the increasing prevalence of psoriatic arthritis, growing demand for biologic therapies, advancements in treatment options, rising awareness of psoriatic arthritis, and healthcare access improvements.

By treatment type, biologics hold the largest share (valued at USD 1,389 million in 2024 and projected to reach USD 3,111 million by 2035), reflecting their increasing acceptance among healthcare providers and effectiveness in managing symptoms. Nonsteroidal anti-inflammatory drugs, corticosteroids, disease-modifying antirheumatic drugs, and targeted synthetic DMARDs also contribute significantly, each offering specific therapeutic benefits for different patient needs.

By route of administration, oral and topical administrations continue to gain traction among patients due to their convenience and ease of use. Injectable options remain relevant, particularly for those requiring immediate effects and targeted delivery, while intravenous options are utilized for severe cases where swift action is required.

By patient type, adult patients considerably comprise the majority holding within this market segment, driven by the prevalence of psoriatic arthritis among this age group in various regions worldwide. Pediatric patients, although a smaller segment, are increasingly recognized as a crucial demographic as awareness of juvenile psoriatic arthritis rises.

By severity of disease, mild cases often involve non-steroidal anti-inflammatory drugs, while moderate cases typically require advanced therapies to effectively manage symptoms and prevent progression. Severe cases, where patients experience significant joint damage and quality of life impairment, are generally treated with biologics and other targeted therapies.

Regionally, North America is anticipated to dominate the market, maintaining a leading role throughout the forecast period, driven by high healthcare expenditure and prevalence of psoriatic arthritis. Europe is expected to hold a significant share, benefiting from advanced healthcare infrastructure and heightened awareness. Asia-Pacific is projected to experience notable growth, driven by increasing patient populations and improving access to treatment options.

Key players include Novartis, Pfizer, Merck, Eli Lilly, Bristol-Myers Squibb, Celgene, UCB, Amgen, Johnson & Johnson, GSK, AbbVie, and Sanofi. Strategies focus on developing innovative biologic therapies, expanding product portfolios, and forming strategic partnerships.

Read more: Global Psoriatic Arthritis Treatment Market Research Report

People Also Ask

Q1. What treatments are available for psoriatic arthritis?
Psoriatic arthritis treatments include nonsteroidal anti-inflammatory drugs, corticosteroids, disease-modifying antirheumatic drugs, biologics, and targeted synthetic DMARDs, offering specific therapeutic benefits for different patient needs and disease severity levels.

Q2. Which region leads the psoriatic arthritis treatment market?
North America leads due to high healthcare expenditure and prevalence of psoriatic arthritis, while Asia-Pacific is emerging rapidly, driven by increasing patient populations and improving access to treatment options.

Tags: psoriatic arthritis treatment, biologics, chronic inflammatory joint disease, nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, pharmaceutical